The purpose of the Core C Biostatistics is to assure that studies conducted through this P01 to develop novel therapeutic strategies in myeloid malignancies are conceptualized under robust principles of statistical design and are analyzed appropriately.
Specific Aim 1. To provide biostatistical collaboration for clinical research protocols. Biologically motivated clinical research protocols in this P01 are conducted through Core D as in vivo human experiments on behalf of the projects. Support by Core C includes all aspects of the design, conduct, analysis, and reporting of the clinical studies, as well as oversight of the electronic data capture mechanism.
Specific Aim 2. To provide biostatistical collaboration for the laboratory research studies. This includes all aspects of the design, conduct, analysis, and reporting of such studies, as well as the association between laboratory results and clinical outcomes both in prospective clinical studies of new agents and in retrospective studies involving sequencing and identification of mutations and their associations with both clinical features of disease and with clinical outcomes. 3. To provide biostatistical collaboration for animal studies, including all aspects of the design and analysis of murine studies.

Public Health Relevance

Core C Biostatistics will assure that all experiments conducted through this P01 in myeloid malignancies will have robust statistical designs and appropriate statistical analysis, to optimize our ability to identify novel therapeutic strategies and improve our understanding of the biology of myeloid malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-16A1
Application #
8666235
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
1997-04-25
Project End
2019-08-31
Budget Start
2014-09-16
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$109,097
Indirect Cost
$15,307
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Wan, Liling; Wen, Hong; Li, Yuanyuan et al. (2017) ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543:265-269
Weisberg, Ellen L; Puissant, Alexandre; Stone, Richard et al. (2017) Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8:52026-52044
Pallis, Monica; Burrows, Francis; Ryan, Jeremy et al. (2017) Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget 8:16220-16232
Tamura, Akihiro; Hirai, Hideyo; Yokota, Asumi et al. (2017) C/EBP? is required for survival of Ly6C- monocytes. Blood 130:1809-1818
Toska, Eneda; Osmanbeyoglu, Hatice U; Castel, Pau et al. (2017) PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355:1324-1330
Shortt, Jake; Ott, Christopher J; Johnstone, Ricky W et al. (2017) A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer 17:160-183
Gonzalez, David; Luyten, Annouck; Bartholdy, Boris et al. (2017) ZNF143 is an important regulator of the myeloid transcription factor C/EBP?. J Biol Chem :
Tothova, Zuzana; Krill-Burger, John M; Popova, Katerina D et al. (2017) Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell 21:547-555.e8
Valerio, Daria G; Xu, Haiming; Chen, Chun-Wei et al. (2017) Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res 77:1753-1762
Li, Hubo; Mar, Brenton G; Zhang, Huadi et al. (2017) The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129:497-508

Showing the most recent 10 out of 303 publications